Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study

Table 2

Baseline patient characteristics.

	Low blood level	High blood level
	𝑛=12	𝑛=13
Age, median (range)	36.0 (29, 53)	42 (27, 50)
Male, 𝑛 (%)	4 (33.3)	3 (23.1)
Relapsing-remitting MS, 𝑛 (%)	7 (58.3)	11 (84.6)
Duration of disease prior to study, median (range)	4.0 (1.0, 5.0)	2.0 (1.0, 7.0)
EDSS in the last year, median (range)	3.5 (1.5, 6.5)	3.5 (1.0, 6.0)
EDSS in the last 2 years, median (range)	2.0 (0.0, 6.5)	2.0 (0.0, 5.0)
Relapses in the last year, median (range)	1.5 (0.0, 3.0)	2.0 (0.0, 5.0)
Relapses in the last 2 years, median (range)	2 (0.0, 5.0)	3.0 (1.0, 7.0)
Number of diseases modifying drugs, median (range)	1 (1, 2)	2 (1, 3)
Mitoxantrone received prior to enrollment, 𝑛 (%)	0 (0.0)	1 (7.7)